Annovis Bio
ANVS

$10.96

4.78%

Market Cap: 122M

About: Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Employees: 6

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 10 analysts

0

News positive %

of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

0.4% less ownership

Funds ownership: 11.74% [Q4 2023] → 11.34% (-0.4%) [Q1 2024]

14% less funds holding

Funds holding: 36 [Q4 2023] → 31 (-5) [Q1 2024]

37% less capital invested

Capital invested by funds: $22.5M [Q4 2023] → $14.3M (-$8.24M) [Q1 2024]

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

51% less call options, than puts

Call options by funds: $12.4M | Put options by funds: $25.4M

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$9

18%

downside

Avg. target

$34

206%

upside

High target

$67

511%

upside

10 analyst ratings

9 positive

90%

1 neutral

10%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju	174%upside $30	Buy Reiterated	17 Jul 2024
HC Wainwright & Co. Raghuram Selvaraju	174%upside $30	Buy Maintained	11 Jul 2024
Rodman & Renshaw Elemer Piros	511%upside $67	Buy Reiterated	2 Jul 2024
HC Wainwright & Co. Raghuram Selvaraju	110%upside $23	Buy Reiterated	12 Jun 2024
Rodman & Renshaw	511%upside $67	Buy Initiated	4 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ANVS published over the past 30 days

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the issuance of a U.S. patent for methods of treating acute traumatic brain injuries (TBI) with its lead drug candidate, buntanetap.

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

Zacks Investment Research

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study

Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study

Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?

Annovis Bio (NYSE: ANVS ) stock closed up a staggering 76% today on promising new data from its Phase 3 clinical study of its Parkinson's treatment, buntanetap. Early results show that its buntanetap is both safe and effective in treating patients with early Parkinson's, helping them retain and improve both motor and non-motor activities and cognitive functions.

Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Annovis Bio Inc.'s stock rocketed 119% on Tuesday after the biotech reported positive results in a late-stage trial of its Parkinson's disease treatment called buntanetap.

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023.

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), today announces that its recent Phase II/III Alzheimer's study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD.

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

Zacks Investment Research

Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet

The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet

Annovis Announces New Publication in a Peer-Reviewed Journal

MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases.

Annovis Announces New Publication in a Peer-Reviewed Journal

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors concerning the Company's possible violations of federal securities laws. On April 29, 2024, Annovis announced that its Alzheimer's drug, buntanetap, had shown significant results in a subgroup of patients. However, the subgroup was a fraction of the total planned patients, indicating that the drug failed to show statistical.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Annovis investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws,.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors

See News Rankings